ClinicalTrials.gg
CompletedNCT00807794Updated Dec 12, 2008

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

A Phase 1 interventional study of MEDI-507 and MEDI-507 in Kidney Diseases, sponsored by MedImmune LLC. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-12-12.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Kidney Diseases by AstraZeneca — none open to participants now, 3 under way, 2 of them phase 3. Kidney Diseases · AstraZeneca.

Started
1997
the only one that year
Phase 1
2 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Kidney Diseases by AstraZeneca, this one is the only one that started in 1997, is one of 2 in phase 1, and was the 3rd registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

None of the 11 studies in Kidney Diseases by AstraZeneca is open now. The open studies under Kidney Diseases, anywhere →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Kidney Diseases by AstraZeneca as a file.
02

Study summary

To evaluate the clinical safety of different doses of MEDI-507 through day 33.

Read the detailed description

To evaluate the pharmacokinetic characteristics of MEDI-507 given in dose intervals.

03

Conditions studied

  • Kidney Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Renal allograft recipients receiving their first or second allograft
  • Age over 18
  • Maintained on conventional
  • Completed document

Exclusion criteria

Exclusion Criteria:

  • Known to MEDI-507
  • More than two renal allografts
  • Moribund and unlikely (in the opinion of the investigator) to survive the duration of the trial
  • Simultaneous use of other agents (this does not include the use of licensed agents for indications not listed in the package insert)
  • Any of the following clinical settings or diagnoses posttransplant:

pregnancy or nursing mother: Ø infection Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator Ø hyperacute rejection

  • Having received OKT3, tacrolimus, or antilymphocyte globulin during the current allograft
  • Less than 10 ml/hr average urine output over 4 hours since the end of surgery
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    1

    MEDI-507

    Drug: MEDI-507

  • Experimental
    2

    MEDI-507

    Drug: MEDI-507

  • Experimental
    3

    MEDI-507

    Drug: MEDI-507

  • Experimental
    4

    MEDI-507

    Drug: MEDI-507

  • Experimental
    5

    MEDI-507

    Drug: MEDI-507

Interventions

  • 0.012 mg/kg dose given twice between 60 to 72 hours apart

  • 0.06 mg/kg dose given twice between 60 to 72 hours apart

  • 0.12 mg/kg dose given twice between 60 to 72 hours apart

  • 0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

  • 0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

06

What researchers measure

Primary outcomes

  1. To evaluate the clinical safety of MEDI-507. Each adverse event will be reported by severity grade, relationship to study drug, organ system, and need for medical intervention.

    Time frame: Day 33

Secondary outcomes

  1. To collect initial pharmacokinetic parameters, the incidence and time to first episode of acute rejection, the number of episodes of rejection and graft survival.

    Time frame: Day 33

07

Study locations

4 sites
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Indiana University
    Bloomington, Indiana 47405, United States
  • San Antonio Community Hospital
    San Antonio, Texas 78229, United States
  • University of Virginia
    Charlottesville,, Virginia 22908, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 1997, a primary completion of Nov 1997 and a completion of Jan 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 12, 2008
Start
Feb 1997
Primary completionActual
Nov 1997
CompletionActual
Jan 1998
Last update
Dec 12, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00807794
Lead sponsor
MedImmune LLC
First posted
Dec 12, 2008
Start date
Feb 1997
Primary completion
Nov 1997
Completion
Jan 1998
Last update
Dec 12, 2008

Study contacts

J. Bruce McClain, M.D.
study director · MedImmune LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion